Research Topics
| A J KrentzSummaryAffiliation: University of Southampton Country: UK Publications
| Collaborators
|
Detail Information
Publications
Oral antidiabetic agents: current role in type 2 diabetes mellitusAndrew J Krentz
Southampton University Hospitals NHS Trust, Southampton, UK
Drugs 65:385-411. 2005..However, intensive lifestyle intervention can be more effective than drug therapy, at least in the setting of interventional clinical trials. No antidiabetic drugs are presently licensed for use in prediabetic individuals...
Vascular disease in the metabolic syndrome: do we need to target the microcirculation to treat large vessel disease?Andrew J Krentz
Institute of Developmental Sciences, School of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK
J Vasc Res 46:515-26. 2009..The hypothesis that vascular events can be prevented, or at least deferred, through earlier therapeutic intervention in pre-diabetic subjects with glucose intolerance is amenable to testing in clinical trials...- Lipoprotein abnormalities and their consequences for patients with type 2 diabetesAndrew J Krentz
Southampton General Hospital, Southampton, UK
Diabetes Obes Metab 5:S19-27. 2003..We now have firm evidence that appropriate use of statins in patients with Type 2 diabetes can significantly reduce cardiovascular morbidity and mortality... - Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complicationsAndrew Krentz
1Department of Diabetes and Endocrinology, Southampton General Hospital, Southampton, UK
Diabetes Metab Res Rev 25:112-26. 2009..Skeletal fractures have recently emerged as a side effect of both TZDs. Available data suggest that cardiovascular benefits observed with pioglitazone might not be a class effect of TZDs... - New drugs for type 2 diabetes mellitus: what is their place in therapy?Andrew J Krentz
Department of Diabetes and Endocrinology, Southampton University Hospitals and University of Southampton, Southampton, UK
Drugs 68:2131-62. 2008..However, the higher cost of these agents, coupled with an absence of long-term safety and clinical outcome data, need to be taken into consideration by clinicians and healthcare organizations... - Management of type 2 diabetes in the obese patient: current concerns and emerging therapiesAndrew J Krentz
Southampton University Hospitals and University of Southampton, Southampton, UK
Curr Med Res Opin 24:401-17. 2008..The aims of this review are (1) to examine the pathophysiologic relationship between type 2 diabetes and obesity, (2) to provide an overview of current and emerging treatments for type 2 diabetes and their effects on body weight... - Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implicationsAndrew J Krentz
Department of Diabetes and Endocrinology, Southampton General Hospital, Southampton SO16 6YD, UK
Diabetes Obes Metab 9:781-91. 2007..Preferential use should be made of drug regimens that (i) maximize vascular protection, (ii) reduce the risk of iatrogenic vascular damage and (iii) minimize the increasing problem of polypharmacy... - New oral agents for type 2 diabetesAndrew J Krentz
Southampton University Hospitals
Clin Med 7:117-8. 2007 - Comparative safety of newer oral antidiabetic drugsAndrew J Krentz
Consultant in Diabetes and Endocrinology, Southampton University Hospitals NHS Trust, University of Southampton, Southampton SO16 6YD, UK
Expert Opin Drug Saf 5:827-34. 2006..alpha-Glucosidase inhibitors have an excellent safety record and acarbose has been shown to retard the progression from impaired glucose tolerance to Type 2 diabetes. However, their use is limited by tolerability issues... - Type 2 diabetes, psoriasis and thiazolidinedionesA J Krentz
Department of Diabetes and Endocrinology and Dermatopharmacology Unit, Southampton General Hospital, UK
Int J Clin Pract 60:362-3. 2006..Further studies are required before the use of thiazolidinediones for psoriasis can be advocated... - Functional dilator capacity is independently associated with insulin sensitivity and age in central obesity and is not improved by high dose statin treatmentGeraldine F Clough
Institute of Developmental Sciences, School of Medicine, University of Southampton, Southampton General Hospital MP 887, Southampton, UK
Microcirculation 18:74-84. 2011.... 
Muscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but is not reversed by high-dose statin treatmentGeraldine F Clough
School of Medicine, University of Southampton, Southampton, UK
Diabetes 58:1185-91. 2009....- Skeletal muscle microvascular exchange capacity is associated with hyperglycaemia in subjects with central obesityM Turzyniecka
School of Medicine, University of Southampton, Southampton, UK
Diabet Med 26:1112-9. 2009..We tested the association between HbA(1c) and a measure of microvascular exchange capacity (K(f)) in skeletal muscle in people with central obesity at risk of developing Type 2 diabetes... - New-onset diabetes after transplantationDavid C Wheeler
Centre for Nephrology, Royal Free and University College Medical School, London
Br J Hosp Med (Lond) 68:190-4. 2007..New-onset diabetes after transplantation has implications for graft and patient survival. This article reviews the pathogenesis, diagnosis and management of new-onset diabetes after transplantation... - Self-image in obesity: clinical and public health implicationsAndrew J Krentz
J R Soc Med 99:215-7. 2006